Market Overview

Nanotherapeutics Announces Name Change to Ology Bioservices, Reflecting the Company's Ongoing Transformation into One of the Top Contract Development and Manufacturing Organizations of Vaccines and Biologics

Share:

Nanotherapeutics, Inc. today announced that the Company has changed its
name to Ology Bioservices, Inc., effective immediately. The name change
is part of a broader rebranding effort and directly reflects the
Company's evolution from a products and formulations company toward its
goal of becoming one of the industry's top contract development and
manufacturing organizations (CDMO), with differentiated expertise in
biologics and vaccines. With its broad service offering, Ology
Bioservices is building a commercial client base consisting of leading
companies focused on research and development of biologics and vaccines
for both preventative and therapeutic use.

"This rebranding reflects our new strategic focus on assisting our
customers in the development and manufacturing of advanced biologics and
vaccines," stated Peter H. Khoury, Ph.D., MBA, President and Chief
Executive Officer of Ology Bioservices. "Our state-of-the-art facility,
which allows for a production environment up to biosafety level 3
(BSL-3) and at a scale of up to 2,000L single-use fermenters, can
deliver process development through commercial scale production of
vaccines, monoclonal antibodies and recombinant proteins for commercial
customers as well as government organizations. We also offer technology
transfer and regulatory services beyond chemistry, manufacturing and
controls (CMC). With this platform, which we believe is the most
comprehensive in the industry, we are uniquely positioned to be the
partner of choice for both public and private-sector organizations
requiring advanced biological manufacturing services."

Ology Bioservices was founded in 1999 under the name Nanotherapeutics,
Inc. From its inception, the Company's growth has been driven by grants
and contracts from both industry and U.S. government agencies, including
National Institutes of Health (NIH), Department of Defense (DoD),
National Cancer Institute (NCI) and Biomedical Advanced Research and
Development Authority (BARDA). Today, Ology Bioservices has grown to
over 185 employees in three locations across the U.S.

In March 2013, DoD awarded the predecessor Company, Nanotherapeutics, a
contract to provide all the core services necessary to establish a
Medical Countermeasures Advanced Development and Manufacturing (MCM ADM)
facility dedicated to meet the specific needs of the DoD. The 10-year,
$400+ million contract had a base period goal for the construction of a
180,000-square foot, state-of-the-art, BSL-3, single-use facility that
Ology Bioservices now occupies and operates. Ology Bioservices plans to
leverage its Medical Countermeasure Readiness capabilities to provide
CDMO services to commercial clients from its ADM facility.

In December 2014, the Company acquired the exclusive, worldwide rights
to the Vero Cell technology and related assets from Baxter
International, Inc. The Vero Cell platform is an advanced, cell-based
technology for vaccine production which Ology Bioservices plans to
out-license to product developers. Dr. Khoury was instrumental in
transacting deals with Takeda, Sanofi and The Serum Institute of India
relating to the utilization of this cell line.

Vitamin D Creative, a full-service advertising and marketing agency
based in Canton, GA, led the rebranding effort. "The brand development
process and resulting name, logo, palette and tagline ‘Capable,
Collaborative, Creative,' truly symbolize the Company's capabilities as
biomanufacturers, collaborative partners and creative scientists and
business partners when needed," stated Dan Malowany, Partner and
Creative Director at Vitamin D Creative agency.

About Ology Bioservices, Inc.

Ology Bioservices, Inc. (formerly Nanotherapeutics, Inc.) is a
biologics-focused contract development and manufacturing organization
(CDMO) serving both government and commercial clients. The Company's
capabilities include a pilot facility for performing optimization of
upstream, downstream and formulation functions, bulk cGMP manufacturing
including biosafety level-3 (BSL-3), and analytical development for
proteins, antibodies, viral vaccines and gene therapy drug products. The
Company provides expertise from preclinical through FDA licensure in a
variety of production platforms, including microbial and mammalian cell
culture and its proprietary serum protein-free Vero cell platform, a
highly versatile platform that has been developed and utilized to
deliver a wide range of candidate and licensed vaccines against emerging
viral diseases.

View Comments and Join the Discussion!